Ransomware Incident Response Checklist for EHR Allergy List Interfaces

How should teams activate and contain an EHR interface incident?

Activate your organization’s incident response and clinical downtime plans as soon as ransomware or unexplained allergy-interface failures are suspected. Use incident command coordination to connect clinical leadership, information security, IT, pharmacy, privacy, communications, and the interface or EHR vendor. Assign a clinical lead to make care-continuity decisions and a technical lead to manage containment and recovery.

With security responders, identify affected systems and interface routes, then isolate compromised components according to the approved response plan. Do not assume an interface is safe because it still appears to be working: stop or restrict affected message flows when needed to prevent corrupted or untrusted data from reaching the allergy list. Use an approved out-of-band channel for urgent coordination, and preserve relevant logs and evidence. CISA’s StopRansomware Guide advises organizations to isolate impacted systems, preserve evidence, and coordinate recovery to avoid reinfection.

Record when the incident was detected, which systems and patient-care locations are affected, what containment actions were taken, and who authorized them. HIPAA’s Security Rule requires covered entities and business associates to respond to and document security incidents; it also requires contingency procedures for backup, recovery, and emergency operations. See 45 C.F.R. § 164.308.

Which downtime workflows protect allergy information during an outage?

Start the approved downtime workflow and tell staff which allergy data sources remain trustworthy, how current they are, and how to access them safely. If using a backup or read-only view, label its last verified date and time; treat older information as potentially incomplete. Keep the current downtime and recovery instructions available to clinical units, as recommended in the ONC SAFER Guide to Contingency Planning.

Use approved, access-controlled downtime forms or systems. Confirm patient identity using the organization’s identification procedure, and record the patient, allergy or intolerance, reaction and severity when known, source of information, time recorded, and staff member documenting it. Clearly label information that has not been verified, and protect completed forms as sensitive patient information.

Do not treat an empty allergy list, a missing interface message, or unavailable history as “no known allergies.” Keep “no known allergies,” “allergies not reviewed,” and “unknown or unable to verify” distinct. For medication decisions during downtime, follow the organization’s downtime medication safety process and escalate cases where allergy information is unavailable or uncertain to the responsible clinician or pharmacist.

How can clinicians verify and document allergies before medication orders?

Before placing an order, review any available trusted allergy history and ask the patient or an appropriate caregiver about medication, food, or other relevant allergies and prior reactions. When possible, corroborate uncertain details using approved clinical records or care-team sources. Do not infer “no known allergies” from silence, a blank field, or a failed interface.

Document what is known and what remains uncertain: the substance, reaction, severity, timing, source, and whether the information was confirmed, when available. If the patient cannot answer and no trustworthy record is accessible, mark the status as unknown or not reviewed using the approved workflow. Seek clinical review before proceeding when the information could affect the safety of the proposed medication.

For systems exchanging HL7 v2 messages, verify that the interface specification correctly handles the applicable allergy fields, such as the AL1 patient allergy information segment, rather than assuming every sender uses identical mappings. The HL7 AL1 segment reference describes fields including allergen, severity, and reaction. Do not convert a missing, rejected, or unmapped segment into a negative allergy assertion.

Keep negative and uncertain statuses distinguishable in the record. HL7 FHIR guidance distinguishes an affirmative statement of no known allergies from allergies not reviewed or not asked about.

What checks are required before restoring allergy interface traffic?

Do not reconnect the interface solely because the EHR or network is available again. The security team should confirm that affected systems and dependencies have been cleared for recovery, and that restoration uses a backup validated for integrity and suitability. HIPAA requires procedures for retrievable data backups and recovery; HHS guidance on ransomware and HIPAA explains the role of contingency and recovery planning.

In a controlled test environment or approved staged process, validate representative messages against the interface specification. Check patient matching, allergen codes and descriptions, reaction and severity fields, verification status, timestamps, acknowledgments, and error handling. Confirm that “no known allergies” remains distinct from “not reviewed,” and that rejected or incomplete messages are visible for follow-up.

Before replaying queued messages, identify duplicates, out-of-order records, and messages that could overwrite newer clinical updates. Agree on a replay plan with interface, clinical, and security leads; monitor the initial production traffic and stop it if validation fails. Document approval, test results, exceptions, and the person responsible for resolving them. These EHR interface message validation and clinical data integrity checks help reduce the risk of silently corrupting allergy records during recovery.

How should teams reconcile allergy records after recovery?

Use a defined allergy reconciliation workflow to compare downtime documentation with the restored EHR and interface records. Work patient by patient, match records using approved identifiers, and account for the downtime entry’s source and time alongside any messages generated during the outage.

Enter missing information through the approved clinical workflow, preserving the original source, author, and timing where the system allows. Review conflicts with the patient or care team rather than automatically overwriting a newer or more specific record. Check for duplicate allergies, missing reactions, incorrect status changes, and records attached to the wrong patient.

Prioritize reconciliation for patients with pending medication orders, administrations, transfers, or other immediate care decisions. Track unresolved discrepancies to a named owner and confirm completion according to local policy. Keep a record of reconciliation and corrections so teams can audit what changed and why.

When should patient-care services be modified or suspended?

Modify or pause an affected service when the responsible clinical leader determines that available allergy information, patient identification, order safeguards, or other essential controls are not reliable enough for safe care. The response may vary by service: a team may be able to continue using a verified downtime process, while another may need to defer a nonurgent medication order or redirect care.

Escalate urgently when an allergy cannot be verified and the uncertainty could materially affect treatment. Use the organization’s clinical escalation pathway to decide whether to obtain additional history, consult pharmacy, select an appropriate alternative, delay a nonurgent action, or transfer care. Do not make a blanket assumption that all services must stop—or that all services may continue—without a patient-specific risk assessment and local leadership direction.

Keep patients and staff informed using approved communication channels, document service changes and their clinical rationale, and reassess as verified data and safe systems become available. A clear incident command, cautious downtime workflow, tested recovery, and documented reconciliation help protect allergy information and support safer care.

FAQs

What should staff do when the EHR allergy interface is unavailable?

Follow the approved downtime process, verify patient identity, consult available trusted allergy sources, and ask the patient or caregiver when possible. Record confirmed information and its source, and clearly mark information that is unknown or not reviewed. Do not interpret a missing message or blank list as “no known allergies”; escalate medication decisions when uncertainty could affect safety.

How can teams distinguish no known allergies from allergies not reviewed?

Use separate status choices and documentation for an affirmative, reviewed statement of no known allergies versus a history that has not been reviewed, not asked, or cannot be verified. HL7 FHIR guidance describes these as distinct concepts. Never create a no-known-allergies status just because allergy data are absent.

What should be validated before restoring interface traffic to production?

Confirm security approval and backup integrity, then test representative messages for patient matching, allergy substance, reaction and severity fields, status mapping, timestamps, acknowledgments, and error handling. Check for duplicate or out-of-order messages and protect newer records from being overwritten. Start traffic in a controlled, monitored manner with clinical and technical approval.

How should downtime allergy records be reconciled after recovery?

Compare downtime documentation with restored and queued records for each patient, resolve conflicts with clinical review, and enter missing information through the approved workflow while preserving source and timing details where possible. Check for duplicates and wrong-patient matches, prioritize active medication decisions, and track unresolved discrepancies to completion.